Modality
Cell Therapy
MOA
DLL3 ADC
Target
TIM-3
Pathway
Fibrosis
ACC
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
Dec 2023
→ May 2028
Phase 2Current
NCT07462278
1,178 pts·ACC
2023-12→2028-05·Completed
1,178 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-222.1y awayPh3 Readout· ACC
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2/3
Complet…
Catalysts
Ph3 Readout
2028-05-22 · 2.1y away
ACC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07462278 | Phase 2/3 | ACC | Completed | 1178 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 | |
| Rimanesiran | Merus | Phase 1 | TIM-3 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| Niratinib | Alumis | NDA/BLA | TIM-3 |